| Catassi, Carlo |
| Completed | 2 | 153 | Europe, Canada, US | TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar | Takeda | Celiac Disease | 11/24 | 11/24 | | |
OxIBDiet, NCT04513015: Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach |
|
|
| Active, not recruiting | N/A | 155 | Europe | Antioxidant diet, Normal dietetic scheme | Università Politecnica delle Marche, Ministry of Health, Italy | Inflammatory Bowel Diseases | 06/24 | 12/24 | | |
| Casella, Michela |
| Recruiting | 3 | 80 | Europe | Colchicine, Treatment, Placebo | Niguarda Hospital, European Union, Ministry of Health, Italy, Mario Negri Institute for Pharmacological Research, University of Milano Bicocca | Cardiomyopathies, Myocarditis, Inflammatory Cardiomyopathy, Heart Failure, Ventricular Arrythmia | 05/26 | 05/28 | | |
PREDICTORS, NCT06085014: Clinical and Electrophysiological Predictors of Arrhythmic Recurrence in Patients With Paroxysmal AF Undergoing First Ablation Procedure of AF by Pulmonary Vein Isolation |
|
|
| Recruiting | N/A | 300 | Europe | Standard of care, Data collection | Centro Cardiologico Monzino, Azienda Ospedaliero, Universitaria Ospedali Riuniti | Atrial Fibrillation Paroxysmal | 09/24 | 09/24 | | |
| Recruiting | N/A | 850 | Europe | | Clinica Mediterranea | Atrial Fibrillation, Catheter Ablation | 12/26 | 12/27 | | |
| Contact, Central |
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy |
|
|
| Completed | 4 | 52 | RoW | Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT) | Astellas Pharma Inc | Metastatic Castration Resistant Prostate Cancer | 02/24 | 02/24 | | |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants |
|
|
| Completed | 3 | 395 | RoW | Enzalutamide, Xtandi, MDV3100, Placebo | Astellas Pharma Inc | Progressive Metastatic Prostate Cancer | 09/15 | 07/24 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
NCT06617897: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery |
|
|
| Recruiting | 3 | 90 | Europe | CSL511 Fibrinogen concentrate (human), Cryoprecipitate | CSL Behring | Acquired Fibrinogen Deficiency | 09/26 | 10/26 | | |
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study ) |
|
|
| Terminated | 3 | 1370 | Europe, US, RoW | BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo | CSL Behring | Traumatic Injury | 10/24 | 10/24 | | |
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation |
|
|
| Active, not recruiting | 2 | 100 | RoW | Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032 | Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU | Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers | 07/15 | 05/18 | | |
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 152 | RoW | Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA) | Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer | Solid Tumors, Colorectal Cancer | 04/18 | 09/18 | | |
| Active, not recruiting | 2 | 100 | US | ALG-055009, Placebo | Aligos Therapeutics | NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis | 11/24 | 12/24 | | |
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder |
|
|
| Recruiting | 2 | 200 | US | Sunobinop, V117957, Placebo to match sunobinop | Imbrium Therapeutics, Purdue Pharma LP | Alcohol Use Disorder | 07/25 | 07/25 | | |
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome |
|
|
| Completed | 1 | 47 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Interstitial Cystitis/Bladder Pain Syndrome | 01/25 | 01/25 | | |
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease |
|
|
| Completed | 1 | 28 | Europe, US | CSL889 | CSL Behring | Sickle Cell Disease | 07/23 | 07/23 | | |
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors |
|
|
| Withdrawn | 1 | 10 | RoW | Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib | Center Trials & Treatment, BioGene Pharmaceutical | Advanced or Recurrent Solid Tumors, Breast Neoplasm | 12/23 | 01/24 | | |
|
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 08/25 | 05/29 | | |
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 175 | US | ASP4396 | Astellas Pharma Inc | Solid Tumor | 04/27 | 04/27 | | |
| Recruiting | 1 | 229 | US | ASP1012, Pembrolizumab | Astellas Pharma Global Development, Inc. | Solid Tumor | 06/29 | 06/29 | | |
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas |
|
|
| Terminated | 1 | 1 | RoW | ASP2802, MACT, MA-20, ASP101G, MicAbody | Astellas Pharma Global Development, Inc. | B-cell Lymphoma | 12/24 | 12/24 | | |
NCT06024642: Study of V117957 in Overactive Bladder Syndrome |
|
|
| Completed | 1 | 51 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Overactive Bladder Syndrome | 05/24 | 05/24 | | |
| Completed | N/A | 1443 | US | | Shire | Hunter Syndrome | 02/23 | 02/23 | | |
NCT05104840: A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus |
|
|
| Terminated | N/A | 2432 | US, RoW | | Center Trials & Treatment, Oleg Martynenko | COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE) | 03/23 | 03/23 | | |
| Recruiting | N/A | 1257 | US | | Shire | Gaucher Disease | 09/25 | 09/25 | | |
NCT06734585: Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant |
|
|
| Recruiting | N/A | 200 | RoW | Gilteritinib, ASP2215, XOSPATA® | Astellas Pharma Singapore Pte. Ltd. | Acute Myeloid Leukemia | 06/25 | 06/25 | | |
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats |
|
|
| Recruiting | N/A | 1000 | US | Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above | Astellas Pharma Global Development, Inc. | Hot Flashes | 02/26 | 11/26 | | |
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 3000 | Japan | Peficitinib, ASP015K, Smyraf | Astellas Pharma Inc | Rheumatoid Arthritis (RA) | 12/25 | 12/25 | | |
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens |
|
|
| Active, not recruiting | N/A | 249 | RoW | Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens | HOYA Lens Thailand LTD. | Myopia | 05/26 | 05/27 | | |
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection |
|
|
| Recruiting | N/A | 202 | RoW | Enfortumab Vedotin, PADCEV, ASG-22CE | Astellas Pharma Korea, Inc., Seagen Inc. | Urothelial Cancer | 07/27 | 07/27 | | |
| Recruiting | N/A | 350 | US | Veye Lung nodules | Aidence | Lung; Node | 07/21 | 07/21 | | |
| Russo, Antonio |
| Recruiting | 2 | 112 | Europe | CPT-11, Calcio levofolinate, 5-Fluorouracil, Capecitabine, Temozolomide | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Neuroendocrine Carcinoma | 01/22 | 01/22 | | |
| Active, not recruiting | 2 | 400 | Europe | Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib | Fondazione per la Medicina Personalizzata | Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer | 12/24 | 06/25 | | |
| Recruiting | N/A | 640 | Europe | Conventional 3-lead CRT defibrillator system implantation, 2-lead CRT defibrillator system implantation | Associazione Portatori Dispositivi Impiantabili Cardiaci | Heart Failure, Cardiac Resynchronization Therapy | 04/25 | 04/25 | | |
| Recruiting | N/A | 500 | Europe | Subcutaneous Implantable Cardioverter Defibrillator | Luigi Sacco University Hospital | Sudden Cardiac Death, Cardiac Arrest, Ventricular Arrythmia, Implantable Cardiac Defibrillator | 12/22 | 12/22 | | |
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 520 | Europe, Canada, US, RoW | FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone | Boston Scientific Corporation | Persistent Atrial Fibrillation | 12/25 | 12/27 | | |
| Active, not recruiting | N/A | 435 | Europe, Canada, US, RoW | Pulsed Field Ablation | Abbott Medical Devices | Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 01/26 | 01/26 | | |
| Completed | N/A | 106 | Europe | AI | University of Rome Tor Vergata | Metastatic Colon Cancer | 03/24 | 11/24 | | |
Key-Early, NCT06467383: A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced |
|
|
| Recruiting | N/A | 600 | Europe | | MSD Italia S.r.l., YGHEA, CRO Division of Ecol Studio spa | Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I | 06/25 | 06/25 | | |
NCT02829437: Observational Study on Endometrial Stromal Tumors |
|
|
| Recruiting | N/A | 100 | Europe | Treatment for EST | Italian Sarcoma Group | Endometrial Stromal Tumors | 12/25 | 12/25 | | |
| Recruiting | N/A | 100 | Europe | Treatment for Epitheloid Sarcoma | Italian Sarcoma Group | Epithelioid Sarcoma | 11/25 | 12/25 | | |
| Recruiting | N/A | 2000 | Europe | Leadless Pacemaker (Micra) | Luigi Sacco University Hospital, Università degli Studi di Brescia, Centro Cardiologico Monzino, University Hospital, Zürich, Azienda Ospedaliera Cardinale G. Panico, Azienda Ospedaliera San Gerardo di Monza, IRCCS Azienda Ospedaliero-Universitaria di Bologna, San Raffaele University Hospital, Italy, Ospedale V. Fazzi, Ospedali Riuniti Ancona, Universitair Ziekenhuis Brussel, Università degli Studi di Ferrara, University of Padova | Block Complete Heart, Atrial Fibrillation | 12/24 | 12/24 | | |
| Recruiting | N/A | 51 | Europe | mini-invasive esophagoscopy, HP-SD AF ablation by a CF sensing catheter | Quovadis Associazione, Abbott | Atrial Fibrillation, Esophageal Perforation, Esophageal Fistula | 07/25 | 10/25 | | |
| Recruiting | N/A | 3000 | Europe | | Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l. | Solid Tumours in Advanced Stages | 10/26 | 10/26 | | |
| Recruiting | N/A | 850 | Europe | | Clinica Mediterranea | Atrial Fibrillation, Catheter Ablation | 12/26 | 12/27 | | |
| Ceravolo, Maria Gabriella |
| Completed | 3 | 507 | Europe, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 01/24 | 02/24 | | |
| Recruiting | N/A | 100 | Europe | | Università Politecnica delle Marche, Maria Gabriella Ceravolo, Michela Coccia, Lauredana Ercolani, Elisa Andrenelli, Lucia Pepa, Rossella Cima, Michela Aringolo | COVID-19 | 12/20 | 06/21 | | |
| Completed | N/A | 103 | Europe | Telerehabilitation | Università Politecnica delle Marche, Universita di Verona | Parkinson Disease | 10/24 | 10/24 | | |
NCT05363046: Noninterventional Study Evaluating Parkinson's Disease Diary Use |
|
|
| Active, not recruiting | N/A | 194 | Europe, Canada, US | | BlueRock Therapeutics | Parkinson's Disease | 10/25 | 10/26 | | |
| Viticchi, Giovanna |
BACH, NCT06537700: OnaBotulinumtoxin-A in Chronic Migraine Patients with Short or Long Disease History (the Study) |
|
|
| Recruiting | N/A | 115 | Europe | OnabotulinumtoxinA OBT-A | Fondazione Policlinico Universitario Campus Bio-Medico | Migraine | 12/24 | 12/25 | | |
